WHO ICTRP trial
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of…
EUCTR2006-003298-28-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-003298-28-GB |
|---|---|
| Public title | A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies. |
| Scientific title | A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies. |
| Primary sponsor | Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England) |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United Kingdom |
| Conditions | Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only). MedDRA version: 8.1 Level: LLT Classification code 10041067 Term: Small cell lung cancer |
| Interventions | Product Name: ABT-263 Product Code: ABT-263 Pharmaceutical Form: Powder for oral solution Current Sponsor code: ABT-263 Other descriptive name: A-855071.3 Concentration unit: g gram(s) Concentration type: not less then Concentration number… |
| Registration date | Oct 16, 2006 |
| Target size | 90 |
| Secondary IDs | M06-822 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: